Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

Factors related to genetic testing in adults at risk for Huntington disease: the prospective Huntington at-risk observational study (PHAROS).

Quaid KA, Eberly SW, Kayson-Rubin E, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators and Coordinators..

Clin Genet. 2016 Oct 14. doi: 10.1111/cge.12893. [Epub ahead of print]

PMID:
27740685
2.

HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD).

Carlozzi NE, Schilling SG, Lai JS, Paulsen JS, Hahn EA, Perlmutter JS, Ross CA, Downing NR, Kratz AL, McCormack MK, Nance MA, Quaid KA, Stout JC, Gershon RC, Ready RE, Miner JA, Barton SK, Perlman SL, Rao SM, Frank S, Shoulson I, Marin H, Geschwind MD, Dayalu P, Goodnight SM, Cella D.

Qual Life Res. 2016 Oct;25(10):2441-55. doi: 10.1007/s11136-016-1386-3.

PMID:
27522213
3.

New measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported outcomes measurement system).

Carlozzi NE, Downing NR, McCormack MK, Schilling SG, Perlmutter JS, Hahn EA, Lai JS, Frank S, Quaid KA, Paulsen JS, Cella D, Goodnight SM, Miner JA, Nance MA.

Qual Life Res. 2016 Oct;25(10):2403-15. doi: 10.1007/s11136-016-1354-y.

PMID:
27393121
4.

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.

Witte MM, Foster NL, Fleisher AS, Williams MM, Quaid K, Wasserman M, Hunt G, Roberts JS, Rabinovici GD, Levenson JL, Hake AM, Hunter CA, Van Campen LE, Pontecorvo MJ, Hochstetler HM, Tabas LB, Trzepacz PT.

Alzheimers Dement (Amst). 2015 Jul 26;1(3):358-67. doi: 10.1016/j.dadm.2015.06.006.

5.

[(11)C]PiB PET in Gerstmann-Sträussler-Scheinker disease.

Deters KD, Risacher SL, Yoder KK, Oblak AL, Unverzagt FW, Murrell JR, Epperson F, Tallman EF, Quaid KA, Farlow MR, Saykin AJ, Ghetti B.

Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):84-93.

6.

NIPT and Informed Consent: an Assessment of Patient Understanding of a Negative NIPT Result.

Piechan JL, Hines KA, Koller DL, Stone K, Quaid K, Torres-Martinez W, Wilson Mathews D, Foroud T, Cook L.

J Genet Couns. 2016 Oct;25(5):1127-37. doi: 10.1007/s10897-016-9945-x.

PMID:
27038428
7.

Erratum to: Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest.

Meslin EM, Rager JB, Schwartz PH, Quaid KA, Gaffney MM, Duke J, Tierney WM.

Clin Transl Med. 2016 Mar;5(1):4. doi: 10.1186/s40169-016-0083-8. No abstract available.

8.

The impact of oculomotor functioning on neuropsychological performance in Huntington disease.

Carvalho JO, Long JD, Westervelt HJ, Smith MM, Bruce JM, Kim JI, Mills JA, Paulsen JS; PREDICT-HD Investigators And Coordinators Of The Huntington Study Group..

J Clin Exp Neuropsychol. 2016;38(2):217-26. doi: 10.1080/13803395.2015.1101054.

PMID:
26745770
9.

Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest.

Meslin EM, Rager JB, Schwartz PH, Quaid KA, Gaffney MM, Duke J, Tierney WH.

Clin Transl Med. 2015 Dec;4(1):36. doi: 10.1186/s40169-015-0077-y. Erratum in: Clin Transl Med. 2016 Dec;5(1):4.

10.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators., Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
11.

Motor onset and diagnosis in Huntington disease using the diagnostic confidence level.

Liu D, Long JD, Zhang Y, Raymond LA, Marder K, Rosser A, McCusker EA, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group..

J Neurol. 2015 Dec;262(12):2691-8. doi: 10.1007/s00415-015-7900-7.

12.

Multivariate clustering of progression profiles reveals different depression patterns in prodromal Huntington disease.

Kim JI, Long JD, Mills JA, McCusker E, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group..

Neuropsychology. 2015 Nov;29(6):949-60. doi: 10.1037/neu0000199.

13.

Performance of the 12-item WHODAS 2.0 in prodromal Huntington disease.

Kim JI, Long JD, Mills JA, Downing N, Williams JK, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group..

Eur J Hum Genet. 2015 Nov;23(11):1584-7. doi: 10.1038/ejhg.2015.11.

14.

A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease.

Green RC, Christensen KD, Cupples LA, Relkin NR, Whitehouse PJ, Royal CD, Obisesan TO, Cook-Deegan R, Linnenbringer E, Butson MB, Fasaye GA, Levinson E, Roberts JS; REVEAL Study Group..

Alzheimers Dement. 2015 Oct;11(10):1222-30. doi: 10.1016/j.jalz.2014.10.014.

15.

Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.

Paulsen JS, Long JD, Ross CA, Harrington DL, Erwin CJ, Williams JK, Westervelt HJ, Johnson HJ, Aylward EH, Zhang Y, Bockholt HJ, Barker RA; PREDICT-HD Investigators and Coordinators of the Huntington Study Group..

Lancet Neurol. 2014 Dec;13(12):1193-201. doi: 10.1016/S1474-4422(14)70238-8.

16.

Genetic counselors' experience with cell-free fetal DNA testing as a prenatal screening option for aneuploidy.

Horsting JM, Dlouhy SR, Hanson K, Quaid K, Bai S, Hines KA.

J Genet Couns. 2014 Jun;23(3):377-400. doi: 10.1007/s10897-013-9673-4.

PMID:
24352524
17.

WHODAS 2.0 in prodromal Huntington disease: measures of functioning in neuropsychiatric disease.

Downing NR, Kim JI, Williams JK, Long JD, Mills JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group..

Eur J Hum Genet. 2014 Aug;22(8):958-63. doi: 10.1038/ejhg.2013.275.

18.

Tracking motor impairments in the progression of Huntington's disease.

Long JD, Paulsen JS, Marder K, Zhang Y, Kim JI, Mills JA; Researchers of the PREDICT-HD Huntington's Study Group..

Mov Disord. 2014 Mar;29(3):311-9. doi: 10.1002/mds.25657.

19.

Natural history of Huntington disease.

Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AF, Biglan KM, Shoulson I; Huntington Study Group COHORT Investigators..

JAMA Neurol. 2013 Dec;70(12):1520-30. doi: 10.1001/jamaneurol.2013.4408.

PMID:
24126537
20.

Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease.

Marder K, Gu Y, Eberly S, Tanner CM, Scarmeas N, Oakes D, Shoulson I; Huntington Study Group PHAROS Investigators..

JAMA Neurol. 2013 Nov;70(11):1382-8. doi: 10.1001/jamaneurol.2013.3487.

Items per page

Supplemental Content

Loading ...
Support Center